59 Result(s)
within
Oncology
Pierre Fenaux
-
Article
Molecular remission as a therapeutic objective in acute promyelocytic leukemia
Acute promyelocytic leukemia (APL) is a subtype of acute leukemia characterized by a unique t(15;17) translocation generating the PML/RARA fusion gene and hybrid oncoprotein. Besides its critical role in leukemog...
-
Article
Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia
-
Article
Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia
-
Article
Open AccessThe impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
-
Article
Autoimmune manifestations associated with myelodysplastic syndromes
Autoimmune disorders (ADs) are encountered in 10 to 20% of patients with myelodysplastic syndromes (MDS). Available data suggest that ADs concern more often younger patients with higher risk IPSS. MDS subtypes...
-
Article
Open AccessMulticenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis
Peripheral blood monocytes include three subsets defined by CD14 and CD16 surface markers. An increase in the CD14++CD16− classical monocyte fraction ≥ 94% of the total monocytes was proposed to rapidly and effic...
-
Article
Open AccessA phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
Erythropoiesis-stimulating agents are first choice for treating anemia in low-risk MDS. This double-blind, placebo-controlled study assessed the efficacy and safety of epoetin-α in IPSS low- or intermediate-1 ...
-
Article
Open AccessTP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Risk stratification is critical in the care of patients with myelodysplastic syndromes (MDS). Approximately 10% have a complex karyotype (CK), defined as more than two cytogenetic abnormalities, which is a hig...
-
Article
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia
Islands of CD123high cells have been commonly described in the bone marrow of patients with chronic myelomonocytic leukemia (CMML). Using a multiparameter flow cytometry assay, we detected an excess of CD123+ mon...
-
Chapter
Treatment Algorithms for Lower-Risk Myelodysplastic Syndrome
Lower-risk myelodysplastic syndromes (MDS) include patients with very low, low, and part of intermediate revised IPSS (i.e., a score below 4), characterized by a low risk of progression to AML, but often promi...
-
Article
Open AccessSingle agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents
-
Article
Open AccessOutcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (media...
-
Article
Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?
Indications of allogeneic hematopoietic stem cell transplantation (HSCT) remain controversial in patients with lower risk myelodysplastic syndrome. We review prognostic factors in lower risk MDS, delineating p...
-
Article
Open AccessImpact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
-
Article
Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study
-
Article
Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy
Intra-tumor heterogeneity portends poor outcome in many cancers. In AML, a higher number of drivers worsens prognosis. The Shannon Index is a robust metric of clonal heterogeneity that accounts for the number ...
-
Article
Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease
-
Article
Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease
-
Article
Open AccessPublisher Correction: Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
-
Article
Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML
The independent prognostic impact of specific dysplastic features in acute myeloid leukemia (AML) remains controversial and may vary between genomic subtypes. We apply a machine learning framework to dissect t...
